Navigation Links
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Date:1/12/2009

Product and Operational Targets Presented At JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced product and operational targets for 2009 that provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the JPMorgan Healthcare Conference in San Francisco, CA.

"The epidemics of diabetes and obesity, which synergistically contribute to cardiovascular disease, are the major health crises of our lifetime," said Bradbury. "The significant unmet need in the diabetes and obesity markets provides an opportunity for Amylin's first-in-class therapies to create tremendous benefit. We look to 2009 to further improve health outcomes for patients, physicians and payors, and to increase shareholder value."

2009 CORPORATE TARGETS

During his remarks, Bradbury highlighted the key 2009 value creation opportunities for Amylin. These targets include the following:

  • Gain approval for an expanded indication of BYETTA as a monotherapy, finalize label updates and return the product to growth
  • Leverage knowledge gained from BYETTA to submit the New Drug Application (NDA) for exenatide once weekly and execute the DURATION head-to-head clinical program designed to show comparative superiority
  • Continue growing SYMLIN revenue
  • Complete obesity clinical trials with amylin/leptin analogs and finalize obesity development and funding strategy
  • Improve operating results and make significant progress toward achieving positive operating cash flow by the end of 2010

Bradbury added, "Our priorities are clear: Grow BYETTA and SYMLIN revenue, submit the NDA for exenatide once weekly and maintain an unwavering focus on managing expenses to achieve positive cash flow by the end of 2010."

A recording of the presentation is accessible through Amylin's corporate Web site, located at www.amylin.com.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Amylin's actual results could differ materially from those discussed due to a number of risks and uncertainties, including the risks that: BYETTA and SYMLIN and the revenues generated from these products may be affected by competition, unexpected new data, and safety and technical issues; clinical trials, including those mentioned in this press release, not being completed in a timely manner, confirming previous results, or achieving the intended clinical endpoints; label expansion requests or NDA filings, including those mentioned in this press release, not being submitted in a timely manner; regulatory approvals being delayed or not received; updates to the BYETTA label not being finalized in a timely manner; our obesity development and funding strategy not being finalized in a timely manner; our expense reductions may not be as large as we expect; or manufacturing and supply issues. The potential for BYETTA and SYMLIN may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's most recent SEC filings including its Quarterly Report on Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Germany and ... -- QGEN ; Frankfurt Prime Standard: QIA) ... QIAseq Targeted RNA Panels for gene expression profiling, expanding ... sequencing (NGS). The panels enable researchers to select from ... fold changes and discover interactions between genes, cellular phenotypes ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:2/11/2016)... Feb. 11, 2016  Vigilant Solutions announces today that its ... being used by Lee,s Summit Police ... location and arrest of a homicide suspect. ... covers around 65 square miles and is home to roughly ... has a single mobile license plate reader system and also ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market report, ... recognition is more widely accepted for border ... both fingerprint and iris recognition technology in ... to avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
Breaking Biology News(10 mins):